{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:28:13Z","timestamp":1762324093248,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.urolonc.2017.05.002","type":"journal-article","created":{"date-parts":[[2017,5,28]],"date-time":"2017-05-28T21:30:44Z","timestamp":1496007044000},"page":"545.e13-545.e18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Experimental validation of the complement protein C3a down expression in the plasma of patients with squamous cell carcinoma of the penis"],"prefix":"10.1016","volume":"35","author":[{"given":"Paulo","family":"Ornellas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilza de M.","family":"Ribeiro-Carvalho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio Augusto","family":"Ornellas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano","family":"Scherrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leandro","family":"Koifman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fulvio","family":"Magni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Helena","family":"Ornellas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilda","family":"Alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2017.05.002_bib1","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1470-2045(04)01427-5","article-title":"Penile carcinoma: a challenge for the developing world","volume":"5","author":"Misra","year":"2004","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2017.05.002_bib2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/jso.20980","article-title":"Surgical treatment of invasive squamous cell carcinoma of the penis: Brazilian National Cancer Institute long-term experience","volume":"97","author":"Ornellas","year":"2008","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.urolonc.2017.05.002_bib3","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1464-410X.1993.tb16273.x","article-title":"Correlation between the extent of nodal involvement and survival following groin dissection for carcinoma of the penis","volume":"72","author":"Ravi","year":"1993","journal-title":"Br J Urol"},{"key":"10.1016\/j.urolonc.2017.05.002_bib4","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.critrevonc.2004.09.006","article-title":"Cancer of the penis","volume":"53","author":"Mosconi","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.urolonc.2017.05.002_bib5","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1590\/1677-553820133806739","article-title":"Downregulation of C3 and C4A\/B complement factor fragments in plasma from patients with squamous cell carcinoma of the penis","volume":"38","author":"Ornellas","year":"2012","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.urolonc.2017.05.002_bib6","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1146\/annurev.immunol.21.120601.141135","article-title":"Does the immune system see tumors as foreign or self?","volume":"21","author":"Pardoll","year":"2003","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.urolonc.2017.05.002_bib7","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.urology.2006.03.052","article-title":"Risk stratification in penile carcinoma: 25-year experience with surgical inguinal lymph node staging","volume":"68","author":"Hungerhuber","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2017.05.002_bib8","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.urolonc.2017.05.002_bib9","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","article-title":"Inflammation and cancer: back to Virchow?","volume":"357","author":"Balkwill","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2017.05.002_bib10","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: a key system for immune surveillance and homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.urolonc.2017.05.002_bib11","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nri3761","article-title":"Complement\u2014tapping into new sites and effector systems","volume":"14","author":"Kolev","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.urolonc.2017.05.002_bib12","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement system Part I\u2014molecular mechanisms of activation and regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.urolonc.2017.05.002_bib13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0161-5890(01)00041-4","article-title":"Anaphylatoxins and infectious and non-infectious inflammatory diseases","volume":"38","author":"Kohl","year":"2001","journal-title":"Mol Immunol"},{"key":"10.1016\/j.urolonc.2017.05.002_bib14","first-page":"1039","article-title":"Persistent complement activation on tumor cells in breast cancer","volume":"140","author":"Niculescu","year":"1992","journal-title":"Am J Pathol"},{"key":"10.1016\/j.urolonc.2017.05.002_bib15","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.it.2004.01.008","article-title":"Complement function in mAb-mediated cancer immunotherapy","volume":"25","author":"Gelderman","year":"2004","journal-title":"Trends Immunol"},{"key":"10.1016\/j.urolonc.2017.05.002_bib16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0161-5890(03)00112-3","article-title":"Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors","volume":"40","author":"Fishelson","year":"2003","journal-title":"Mol Immunol"},{"key":"10.1016\/j.urolonc.2017.05.002_bib17","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/labinvest.3780038","article-title":"A possible role of CD46 for the protection in vivo of human renal tumor cells from complement mediated damage","volume":"80","author":"Blok","year":"2000","journal-title":"Lab Invest"},{"key":"10.1016\/j.urolonc.2017.05.002_bib18","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1159\/000069451","article-title":"Clinical implications of natural killer cytotoxicity in patients with squamous cell carcinoma of the penis","volume":"6","author":"Campos","year":"1998","journal-title":"Nat Immun"},{"key":"10.1016\/j.urolonc.2017.05.002_bib19","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/978-1-4614-5915-6_11","article-title":"The role of complement in tumor growth","volume":"772","author":"Pio","year":"2014","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.urolonc.2017.05.002_bib20","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/1521-4141(200201)32:1<128::AID-IMMU128>3.0.CO;2-P","article-title":"Enhancement of the complement activating capacity of 17-1A mAb to overcome the effect of membrane-bound complement regulatory proteins on colorectal carcinoma","volume":"32","author":"Gelderman","year":"2002","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.urolonc.2017.05.002_bib21","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1001\/jama.2016.2240","article-title":"Biomarkers and surrogate endpoints developing common terminology and definitions","volume":"315","author":"Robb","year":"2016","journal-title":"J Am Med Assoc"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143917302120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143917302120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:10:59Z","timestamp":1761041459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143917302120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S1078143917302120"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2017.05.002","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Experimental validation of the complement protein C3a down expression in the plasma of patients with squamous cell carcinoma of the penis","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2017.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}